Gynecologic Cancer

Felix Blanc-Durand, Elisa Yaniz, Catherine Genestie, et al.
The study authors evaluated a novel functional assay of HR functionality in advanced EOC. They demonstrated the following results:
  • The assay requires minimal tissue and yields contributive results in 90% of cases.  
  • EOC has high levels of basal DNA damage, 55% fail to recruit RAD51 foci during S/G2 cell cycle phase.
  • These RAD51-deficient EOC have improved outcomes after neoadjuvant platinum therapy.
  • The RAD51 assay also identified a small subset of RAD51-high BRCAmut tumors with a poor platinum response. 
Patricia Pautier, Philipp Harter, Carmela Pisano, et al.
The study authors conclude that In the PAOLA-1 study, maintenance olaparib plus bevacizumab provided a progression-free survival and PFS2 benefit over placebo plus bevacizumab in HRD+ patients, irrespective of FIGO stage and residual disease after upfront surgery. Clinical trial information: NCT02477644
Cara Amanda Mathews, Fiona Simpkins, Karen Anne Cadoo, et al.
The study authors conclude with their final analysis that 18-month overall survival ranged from 60–88% across the 4 cohorts.
The 18-month overall survival rate was highest in the BRCAm cohorts (similar overall survival in g and sBRCAm); among patients without a BRCAm, 18-month overall survival was highest in the HRD +ve cohort.
Compared with the primary analysis and with prior olaparib studies there were no new safety signals observed. Clinical trial information: NCT02983799
Stephanie L. Wethington, Payal D Shah, Lainie P. Martin, et al.
The study authors conclude that olaparib plus ceralasertib is well tolerated and shows clinical activity in recurrent HRD HGSOC after progressing on prior PARPi. This is the first time a study is suggesting the potential of ATR inhibitors to overcome PARPi resistance in an HRD patient population. Clinical trial information: NCT03462342
Amit M. Oza, Alla Sergeevna Lisyanskaya, Alexander A. Fedenko, et al.
The study authors conclude that that rucaparib is a reasonable treatment option for heavily pretreated patients across all platinum sensitivity subgroups. There were no new safety signals compared with prior rucaparib studies. Clinical trial information: NCT02855944
Antonio Gonzalez Martin, Ursula A. Matulonis, Jacob Korach, et al.
The study authors conclude that Patients with BRCAm OC derived a significant progression-free survival benefit from niraparib maintenance treatment across all 3 trials. There were no new safety signals identified. Clinical trial information: NCT02655016,  NCT01847274,  NCT03705156
Rachel N. Grisham, Ignace Vergote, Susana N. Banerjee, et al.
The study authors conclude that higher response rates and longer progression-free survival were seen in those patients with LGSOC treated with binimetinib who harbored MAPK mutations, most commonly in KRAS. However, this is a hypothesis generating analysis limited by multiple testing. The authors recommend, that somatic tumor testing should be routinely performed in patients with recurrent LGSOC to aid in clinical decision making. Clinical trial information: NCT01849874
JUNG-YUN LEE, Byoung-Gie Kim, Jae-Weon Kim, et al.
The study authors conclude that in this first biomarker-driven umbrella study in patients with platinum-resistant recurrent ovarian cancer preliminary evidence is provided on the clinical benefit of biomarker-driven targeted therapy. All regimens were manageable, and no unexpected toxicities were observed. Clinical trial information: NCT03699449
Lukas Rob, David Cibula, Pawel Knapp, et al.
The study authors conclude that an autologous immunotherapy with Dendritic-cell vaccine improved progression-free and overall survival outcomes in patients with newly diagnosed EOC. This was predominantly observed in patients with immunologically “cold” tumors, thus representing a promising treatment option in this patient population. Clinical trial information: NCT02107937
The study authors conclude that the combination was well tolerated and demonstrated clinical benefit in 74% platinum resistant ovarian cancer patients with a durable response (>6 months) in 53% of patients. Clinical trial information: NCT03596281
Dana M Roque, Stefania Bellone, Eric R. Siegel, et al.
The study authors conclude that their study demonstrated prognostic significance of Lynch-like versus sporadic MSI-H EC on ORR, progression-free and overall survival when treated with pembrolizumab. Clinical trial information: NCT02899793
Qin Xu, Chuanben Chen, Yang Sun, et al.
The study authors conclude that Anlotinib - a novel multi-target tyrosine kinase inhibitor - plus sintilimab - a fully humanized, high-affinity monoclonal antibody against programmed cell death-1 (PD-1) - showed a promising efficacy with a favorable toxicity profile for patients with recurrent advanced cervical cancer. Clinical trial information: ChiCTR1900023015.